The treatment with IG-1 for 7 or 28 days reduces daily food intakes, body weights, and fasting plasma concentrations of glucose, insulin, triglyceride and free fatty acids, and hepatic triglyceride contents in mice models of type 2 diabetes, obesity and metabolic syndrome (table 1 and 2). Here, INS is linked to type 2 diabetes mellitus.